Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

OBJECTIVE: To study the impact of the 79A>C polymorphism in the cytidine deaminase (CDA) gene on the pharmacokinetics of gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine (dFdU) in non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Patients (n = 20) received gemcitabine 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maring, Jan Gerard, Wachters, Floris M., Slijfer, Monique, Maurer, J. Marina, Boezen, H. Marike, Uges, Donald R. A., de Vries, Elisabeth G. E., Groen, Harry J. M.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868996/
https://www.ncbi.nlm.nih.gov/pubmed/20213492
http://dx.doi.org/10.1007/s00228-010-0799-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868996/
https://www.ncbi.nlm.nih.gov/pubmed/20213492
http://dx.doi.org/10.1007/s00228-010-0799-0

Ejemplares similares